Boosting Bovine Immunity: Can a Recombinant Protein Ward Off Herpes?
"Innovative vaccine strategy shows promise in protecting cattle against bovine herpesvirus types 1 and 5, offering new hope for reducing economic losses in the livestock industry."
Bovine herpesvirus type 5 (BoHV-5) poses a significant threat to young cattle, often leading to outbreaks of meningoencephalitis with high mortality rates, resulting in substantial economic losses for farmers. Current strategies to combat this virus, like using vaccines against the related bovine herpesvirus type 1 (BoHV-1), offer some cross-protection but aren't always sufficient.
Recognizing the need for more effective solutions, scientists have been exploring subunit vaccines that target key viral components. Glycoprotein D (gD) is crucial for the herpesvirus's ability to attach to and enter host cells. This makes gD a prime target for vaccine development because it can stimulate strong immune responses.
This article delves into a recent study investigating the potential of a recombinant form of BoHV-5 glycoprotein D (rgD5) as a vaccine antigen in cattle. We'll explore how the researchers formulated and tested vaccines containing rgD5, and what their findings suggest for the future of bovine herpesvirus prevention.
A Widespread Cattle Pathogen
Bovine herpesvirus type 1 (BoHV-1, also called BHV-1) causes infectious bovine rhinotracheitis, an upper respiratory tract infection, and is described as highly contagious. It occurs worldwide and is endemic in a number of food-producing countries. In the Republic of Ireland, a 2020–2023 prospective field study followed seroprevalence on fifteen dairy farms with 85–250 cows each; the source notes there is no current formal eradication programme there. The supplied sources establish the disease’s reach and ongoing monitoring, but do not provide a single overall prevalence figure.
The Challenge of Lifelong Latency
A 2023 review describes BoHV-1 as a persistent, recurring infection that contributes to bovine respiratory disease and reproductive failure in the United States. It identifies a key complication: after acute infection, the virus establishes lifelong latency in sensory ganglia of the peripheral nervous system. The review focuses on the latency–reactivation cycle and its molecular mechanisms, framing that cycle as a chronic problem for the cattle industry. An earlier review also covered BoHV-1 biology, its role in the bovine respiratory disease complex, and development of improved vaccines.
Unlocking gD5: A New Approach to Bovine Herpesvirus Vaccines
The study, conducted by researchers in Brazil, involved vaccinating 72 heifers with different vaccine formulations. These formulations included inactivated BoHV-5 (iBoHV-5), recombinant gD5 (rgD5), and adjuvants (substances that boost the immune response). The researchers compared these experimental vaccines against a commercial vaccine and a control group that received a placebo.
- Group 1: Inactivated BoHV-5 (iBoHV-5) with ISA50V2 adjuvant
- Group 2: iBoHV-5 + 100 µg rgD5 with ISA50V2 adjuvant
- Group 3: 100 µg rgD5 with ISA50V2 adjuvant
- Group 4: 100 µg rgD5 with Al(OH)3 adjuvant
- Group 5: Commercial vaccine
- Group 6: Control group (placebo)
Protein-Based Vaccine Research
A preprint titled “Recombinant BoHV-5 Glycoprotein Elicits Long-Lasting Protective Immunity in Cattle” concerns BoHV-5, a worldwide-distributed pathogen usually associated with lethal neurological disease (meningoencephalitis) in dairy and beef cattle. Separately, a 2025 study reports a bivalent BoHV-1 subunit vaccine based on the ectodomains of glycoproteins D and B that elicited robust protective immunity in a rabbit model. Research on glycoprotein B domains has also examined their expression in Komagataella phaffii. The supplied source says glycoprotein D candidates have shown better results than commercial inactivated virus vaccine but have not prevented neuroinvasion and viral reactivation.
Reproductive Safety and Vaccine Limits
Modified-live BoHV-1 vaccines raise reproductive-safety concerns when maximal reproduction is the goal, with a 2017 review examining their effects on conception and fetal survival in cows and heifers. BoHV-1 is also associated with respiratory and genital disease and late-term abortions. Control in many parts of the world relies primarily on vaccination with either inactivated or modified-live vaccines. These sources describe the need to weigh disease control against reproductive outcomes, but the supplied snippets do not quantify the risks.
The Future of Bovine Herpesvirus Prevention
The research indicates that vaccines formulated with inactivated BoHV-5 and recombinant gD5 triggered a significant increase in total immunoglobulin G (IgG) levels for BoHV-5, BoHV-1, and rgD5, suggesting a strong overall immune response. The vaccines also stimulated the production of IgG1 and IgG2a, specific antibody subtypes, against rgD5.
Developing Recombinant BoHV Vectors
A 2025 review considers bovine herpesvirus-based vectors for recombinant vaccines against bovine and zoonotic pathogens. It discusses the current state of the field, prospects, and strategies for future research, with the aim of improving vaccine efficacy. A separate 2025 review is focused on diagnostic techniques and vaccine development for BoHV-1, which it describes as a major cause associated with bovine respiratory disease and widely prevalent across global cattle populations. Together, the sources point to continued work on both vaccine platforms and diagnostics, without specifying a particular future product or timetable.
Vaccine Promise and Field Challenges
Recombinant herpesvirus vaccine vectors can establish persistent infections, an attribute the source presents as a way to sustain antigen responses in the host. Field experience also shows that vaccination does not guarantee success in every animal: an outbreak-control report described two BoHV-1-positive animals that developed meningoencephalitis despite vaccination and revaccination, characterizing this as vaccinal failure. A 2021 field-evaluation study describes BoHV-1 as associated with respiratory and genital disease, infertility, and abortions, and notes that control commonly relies on inactivated or live modified viral vaccines. These reports show both the proposed benefit of recombinant vectors and the practical limits documented in cattle vaccination.
Importantly, the vaccines containing rgD5 led to higher titers of neutralizing antibodies against both BoHV-1 and BoHV-5. This is promising because it demonstrates that rgD5 contains key viral components capable of stimulating a protective immune response against both viruses.
These findings suggest that rgD5 holds significant potential as a vaccine antigen for use in BoHV-1 and BoHV-5 endemic areas. Further research is needed to optimize vaccine formulations and delivery methods, rgD5 could play a key role in preventing outbreaks and minimizing economic losses in the cattle industry.